Deloitte Health&BioTech Accelerator

Deloitte Officine Innovazione has launched a new scale-up program dedicated to the future of health and biotech. The selected finalists of the call will work together with the project corporate partners to develop innovative pilot projects to enhance their core business or launch new solutions on the market.

 

With the launch of the Health&BioTech Accelerator players from different industries in Milano, Europe and beyond converge to face the challenges of a more effective technology transfer process with the support of key partners of the local health and wellness industry and academics including: MSD Italia and Intesa Sanpaolo RBM Salute, GVM Care & Research, Humanitas Research Hospital, Santagostino and Casa di Cura La Madonnina, Istituto Italiano di Tecnologia (IIT), Università degli Studi di Milano and IFOM - Istituto FIRC di Oncologia Molecolare, Italian Angels for Growth, Digital Magics, Panakès Partners, SMAU and MakingLife.

 

The goal of the accelerator is to develop pilot projects, integrating the innovative solutions of startups and scaleups with the skills and assets provided by partners, to enhance the core business of corporations or launch new solutions on the market.

Phases

The project is based in Italy but has an international scope and it developes across three macro-phases:

  1. Applications from startups and scaleups are open from December 10, 2020 until February 28, 2021 – the website to apply is www.healthbiotechaccelerator.io

    International startups and scaleups with innovative solutions related to these 8 identified trends are invited to apply:
    • New Drugs & Therapies
    • Biomarkers & Diagnostic Tools
    • Carriers & Delivery Systems
    • Advanced & Digital Diagnostics
    • Innovative Care Management
    • Telehealth
    • Healthcare Robotics
    • Healthy Lifestyle
     

  2. Selection - February - April 2021: applications will be analyzed and the most innovative solutions will be selected thanks to the expertise of the companies, research centers and venture capitalists taking part in the project.
  3. Acceleration - from April 2021 the most intense phase of the program will begin, it will last 15 weeks during which corporations, partners and selected startups/scaleups will work together in order to develop pilot projects that will be presented during the Demo Day, the final moment of presentation to the public and the business innovation community.

 

For more information on the accelerator visit www.healthbiotechaccelerator.io